Hot Investor Profile: Newly Established VC Firm Seeks Seed Stage Companies in AI, Synthetic Biology, Cell/Gene Therapy Companies in the US 

16 Oct

A newly founded venture capital firm headquartered in the US is interested in Seed stage companies that focus on gene tech (DNA, RNA, proteins, and cells). Typical check size is expected to be around USD $500k and the firm will typically not lead rounds. Companies can have their headquarters elsewhere; however, the firm requires companies to be U.S. Incorporated. 
 
In terms of healthcare, the firm is interested in diagnostics using DNA, RNA, or proteins, cell and gene therapy, engineered vaccines, antibiotics, longevity and health span improvements, software and data, bioinformatic solutions, platforms, and AI-powered solutions. The firm is not interested in small molecules and medical devices. 

The firm does not have strict company or management team requirements. The firm does not require to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment